Loading...
Loading...
CWBR| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 2,470.8K |
| Operating I/L | -2,470.8K |
| Other Income/Expense | 78.9K |
| Interest Income | 78.9K |
| Pretax | -2,391.9K |
| Income Tax Expense | -78.9K |
| Net Income/Loss | -2,313.0K |
CohBar, Inc. is a clinical stage biotechnology company specializing in mitochondria-based therapeutics for chronic and age-related diseases. The company's lead clinical candidate, CB4211, is a refined analog of the MOTS-c mitochondrial derived peptide, currently in Phase Ib of a Phase Ia/Ib clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. CohBar's focus on developing MBTs for a range of conditions including NASH, obesity, fibrotic diseases, and COVID-19 associated ARDS positions it at the forefront of innovative treatments for these prevalent health issues.
